Cargando…
Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study
BACKGROUND AND PURPOSE: Neurological sequelae from coronavirus disease 2019 (COVID‐19) may persist after recovery from acute infection. Here, the aim was to describe the natural history of neurological manifestations over 1 year after COVID‐19. METHODS: A prospective, multicentre, longitudinal cohor...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111823/ https://www.ncbi.nlm.nih.gov/pubmed/35239247 http://dx.doi.org/10.1111/ene.15307 |
_version_ | 1784709309332979712 |
---|---|
author | Rass, Verena Beer, Ronny Schiefecker, Alois Josef Lindner, Anna Kofler, Mario Ianosi, Bogdan Andrei Mahlknecht, Philipp Heim, Beatrice Peball, Marina Carbone, Federico Limmert, Victoria Kindl, Philipp Putnina, Lauma Fava, Elena Sahanic, Sabina Sonnweber, Thomas Löscher, Wolfgang N. Wanschitz, Julia V. Zamarian, Laura Djamshidian, Atbin Tancevski, Ivan Weiss, Günter Bellmann‐Weiler, Rosa Kiechl, Stefan Seppi, Klaus Loeffler‐Ragg, Judith Pfausler, Bettina Helbok, Raimund |
author_facet | Rass, Verena Beer, Ronny Schiefecker, Alois Josef Lindner, Anna Kofler, Mario Ianosi, Bogdan Andrei Mahlknecht, Philipp Heim, Beatrice Peball, Marina Carbone, Federico Limmert, Victoria Kindl, Philipp Putnina, Lauma Fava, Elena Sahanic, Sabina Sonnweber, Thomas Löscher, Wolfgang N. Wanschitz, Julia V. Zamarian, Laura Djamshidian, Atbin Tancevski, Ivan Weiss, Günter Bellmann‐Weiler, Rosa Kiechl, Stefan Seppi, Klaus Loeffler‐Ragg, Judith Pfausler, Bettina Helbok, Raimund |
author_sort | Rass, Verena |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Neurological sequelae from coronavirus disease 2019 (COVID‐19) may persist after recovery from acute infection. Here, the aim was to describe the natural history of neurological manifestations over 1 year after COVID‐19. METHODS: A prospective, multicentre, longitudinal cohort study in COVID‐19 survivors was performed. At a 3‐month and 1‐year follow‐up, patients were assessed for neurological impairments by a neurological examination and a standardized test battery including the assessment of hyposmia (16‐item Sniffin' Sticks test), cognitive deficits (Montreal Cognitive Assessment < 26) and mental health (Hospital Anxiety and Depression Scale and Post‐traumatic Stress Disorder Checklist 5). RESULTS: Eighty‐one patients were evaluated 1 year after COVID‐19, out of which 76 (94%) patients completed a 3‐month and 1‐year follow‐up. Patients were 54 (47–64) years old and 59% were male. New and persistent neurological disorders were found in 15% (3 months) and 12% (10/81; 1 year). Symptoms at 1‐year follow‐up were reported by 48/81 (59%) patients, including fatigue (38%), concentration difficulties (25%), forgetfulness (25%), sleep disturbances (22%), myalgia (17%), limb weakness (17%), headache (16%), impaired sensation (16%) and hyposmia (15%). Neurological examination revealed findings in 52/81 (64%) patients without improvement over time (3 months, 61%, p = 0.230) including objective hyposmia (Sniffin' Sticks test <13; 51%). Cognitive deficits were apparent in 18%, whereas signs of depression, anxiety and post‐traumatic stress disorders were found in 6%, 29% and 10% respectively 1 year after infection. These mental and cognitive disorders had not improved after the 3‐month follow‐up (all p > 0.05). CONCLUSION: Our data indicate that a significant patient number still suffer from neurological sequelae including neuropsychiatric symptoms 1 year after COVID‐19 calling for interdisciplinary management of these patients. |
format | Online Article Text |
id | pubmed-9111823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91118232022-05-17 Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study Rass, Verena Beer, Ronny Schiefecker, Alois Josef Lindner, Anna Kofler, Mario Ianosi, Bogdan Andrei Mahlknecht, Philipp Heim, Beatrice Peball, Marina Carbone, Federico Limmert, Victoria Kindl, Philipp Putnina, Lauma Fava, Elena Sahanic, Sabina Sonnweber, Thomas Löscher, Wolfgang N. Wanschitz, Julia V. Zamarian, Laura Djamshidian, Atbin Tancevski, Ivan Weiss, Günter Bellmann‐Weiler, Rosa Kiechl, Stefan Seppi, Klaus Loeffler‐Ragg, Judith Pfausler, Bettina Helbok, Raimund Eur J Neurol Infectious Diseases BACKGROUND AND PURPOSE: Neurological sequelae from coronavirus disease 2019 (COVID‐19) may persist after recovery from acute infection. Here, the aim was to describe the natural history of neurological manifestations over 1 year after COVID‐19. METHODS: A prospective, multicentre, longitudinal cohort study in COVID‐19 survivors was performed. At a 3‐month and 1‐year follow‐up, patients were assessed for neurological impairments by a neurological examination and a standardized test battery including the assessment of hyposmia (16‐item Sniffin' Sticks test), cognitive deficits (Montreal Cognitive Assessment < 26) and mental health (Hospital Anxiety and Depression Scale and Post‐traumatic Stress Disorder Checklist 5). RESULTS: Eighty‐one patients were evaluated 1 year after COVID‐19, out of which 76 (94%) patients completed a 3‐month and 1‐year follow‐up. Patients were 54 (47–64) years old and 59% were male. New and persistent neurological disorders were found in 15% (3 months) and 12% (10/81; 1 year). Symptoms at 1‐year follow‐up were reported by 48/81 (59%) patients, including fatigue (38%), concentration difficulties (25%), forgetfulness (25%), sleep disturbances (22%), myalgia (17%), limb weakness (17%), headache (16%), impaired sensation (16%) and hyposmia (15%). Neurological examination revealed findings in 52/81 (64%) patients without improvement over time (3 months, 61%, p = 0.230) including objective hyposmia (Sniffin' Sticks test <13; 51%). Cognitive deficits were apparent in 18%, whereas signs of depression, anxiety and post‐traumatic stress disorders were found in 6%, 29% and 10% respectively 1 year after infection. These mental and cognitive disorders had not improved after the 3‐month follow‐up (all p > 0.05). CONCLUSION: Our data indicate that a significant patient number still suffer from neurological sequelae including neuropsychiatric symptoms 1 year after COVID‐19 calling for interdisciplinary management of these patients. John Wiley and Sons Inc. 2022-03-23 2022-06 /pmc/articles/PMC9111823/ /pubmed/35239247 http://dx.doi.org/10.1111/ene.15307 Text en © 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Infectious Diseases Rass, Verena Beer, Ronny Schiefecker, Alois Josef Lindner, Anna Kofler, Mario Ianosi, Bogdan Andrei Mahlknecht, Philipp Heim, Beatrice Peball, Marina Carbone, Federico Limmert, Victoria Kindl, Philipp Putnina, Lauma Fava, Elena Sahanic, Sabina Sonnweber, Thomas Löscher, Wolfgang N. Wanschitz, Julia V. Zamarian, Laura Djamshidian, Atbin Tancevski, Ivan Weiss, Günter Bellmann‐Weiler, Rosa Kiechl, Stefan Seppi, Klaus Loeffler‐Ragg, Judith Pfausler, Bettina Helbok, Raimund Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study |
title | Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study |
title_full | Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study |
title_fullStr | Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study |
title_full_unstemmed | Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study |
title_short | Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study |
title_sort | neurological outcomes 1 year after covid‐19 diagnosis: a prospective longitudinal cohort study |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111823/ https://www.ncbi.nlm.nih.gov/pubmed/35239247 http://dx.doi.org/10.1111/ene.15307 |
work_keys_str_mv | AT rassverena neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT beerronny neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT schiefeckeraloisjosef neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT lindneranna neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT koflermario neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT ianosibogdanandrei neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT mahlknechtphilipp neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT heimbeatrice neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT peballmarina neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT carbonefederico neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT limmertvictoria neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT kindlphilipp neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT putninalauma neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT favaelena neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT sahanicsabina neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT sonnweberthomas neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT loscherwolfgangn neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT wanschitzjuliav neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT zamarianlaura neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT djamshidianatbin neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT tancevskiivan neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT weissgunter neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT bellmannweilerrosa neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT kiechlstefan neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT seppiklaus neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT loefflerraggjudith neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT pfauslerbettina neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy AT helbokraimund neurologicaloutcomes1yearaftercovid19diagnosisaprospectivelongitudinalcohortstudy |